EC
Euclidean Capital Portfolio holdings
AUM
$306M
This Quarter Return
-4.47%
1 Year Return
+16.69%
3 Year Return
+17.66%
5 Year Return
–
10 Year Return
–
AUM
$458M
AUM Growth
+$458M
(+18%)
Cap. Flow
+$93.3M
Cap. Flow
% of AUM
20.36%
Top 10 Holdings %
Top 10 Hldgs %
99.63%
Holding
13
New
1
Increased
8
Reduced
–
Closed
–
Top Buys
| 1 |
SPDR Gold Trust
GLD
|
$87M |
| 2 |
Alector
ALEC
|
$2.12M |
| 3 |
Oric Pharmaceuticals
ORIC
|
$1.46M |
| 4 |
RAPT Therapeutics
RAPT
|
$1.44M |
| 5 |
PMV Pharmaceuticals
PMVP
|
$506K |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 13.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
SPDR Gold Trust
GLD
$110B
| $182M | 39.74% |
1,062,500
+507,500
| +91% | +$87M |
|
2
iShares MSCI India ETF
INDA
$9.24B
| $107M | 23.4% |
2,425,144
| – | – |
|
3
SPDR S&P 500 ETF Trust
SPY
$653B
| $105M | 22.96% |
246,250
| – | – |
|
|
4
PMV Pharmaceuticals
PMVP
$79.5M
| $16.1M | 3.52% |
2,627,643
+82,401
| +3% | +$506K |
|
|
5
RAPT Therapeutics
RAPT
$193M
| $10.9M | 2.39% |
657,899
+86,666
| +15% | +$1.44M |
|
|
ME
6
DELISTED
23andMe Holding Co. Class A Common Stock
ME
| $10M | 2.18% |
10,243,122
| – | – |
|
|
7
Alector
ALEC
$261M
| $8.47M | 1.85% |
1,307,858
+326,964
| +33% | +$2.12M |
|
8
Foghorn Therapeutics
FHTX
$299M
| $7.87M | 1.72% |
1,573,761
| – | – |
|
|
9
Oric Pharmaceuticals
ORIC
$1.01B
| $5.99M | 1.31% |
989,410
+241,860
| +32% | +$1.46M |
|
10
Tenaya Therapeutics
TNYA
$176M
| $2.59M | 0.57% |
1,015,705
+100,000
| +11% | +$255K |
|
|
NGM
11
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
| $1.06M | 0.23% |
992,168
+245,494
| +33% | +$263K |
|
12
Surrozen
SRZN
$105M
| $645K | 0.14% |
1,315,463
+512,500
| +64% | +$251K |
|
|
13
Surrozen, Inc. Warrant
SRZNW
$71.9K
| $7.02K | ﹤0.01% |
+170,833
| New | +$7.02K |
|